Public Market Listing
2696 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (14 total) 14 Total Assets
0 Approved
6 Phase 3 / Filed
8 Phase 1–2 / Early
8 Diseases
Disease: All diseases (14) Non-Small Cell Lung Cancer (11) Rheumatoid Arthritis (1) Colorectal Cancer (1) Age-Related Macular Degeneration (1) Multiple Myeloma (1) Small Cell Lung Cancer (1) Gastric Cancer (1) Breast Cancer (1)
Stage: All stages (14) Approved / Phase 4 (0) Phase 3 / Filed (6) Phase 2 Phase 1 / Preclinical
Quick filter: All (14) Non-Small Cell Lung Cancer (11) Rheumatoid Arthritis (1) Colorectal Cancer (1) Age-Related Macular Degeneration (1) Multiple Myeloma (1)
Showing 14 of 14 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 EGFR Small molecule
Non-Small Cell Lung Cancer
HLX01 (Hanlikang) No recent activity Phase 3 CD20 Monoclonal antibody
Phase 3 VEGF-A Monoclonal antibody
Non-Small Cell Lung Cancer Colorectal Cancer
Phase 3 VEGF-A Monoclonal antibody
Age-Related Macular Degeneration
Phase 3 CD38 Monoclonal antibody
Phase 3 PD-1 Monoclonal antibody
Non-Small Cell Lung Cancer Small Cell Lung Cancer Gastric Cancer
Phase 2/3 PD-L1 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer
HR+/HER2- Metastatic Breast Cancer Phase 2/3 EGFR Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 2 BRAF V600E Small molecule
Non-Small Cell Lung Cancer
Phase 2 LAG-3 Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1/2 BRAF V600E + PD-1 (combination regimen) Combination
Non-Small Cell Lung Cancer
Phase 1/2 PD-L1 / TIGIT Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1 EGFR x 4-1BB (CD137) Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1 EGFR Antibody–drug conjugate
Non-Small Cell Lung Cancer
Upcoming events (14 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (4) November 2026 (1) HLX43 Phase 2 Nasopharyngeal Carcinoma (NPC) Est. primary completion 2026-11-22 ·
NCT06839066 ·
CT.gov ↗ What to watch
December 2026 (3) HLX43 Phase 2 Hormone Receptor Positive HER-2 Negative Breast Cancer Est. primary completion 2026-12-30 ·
NCT07459738 ·
CT.gov ↗ What to watch
HLX43 Phase 2 Colorectal Cancer (CRC) Est. primary completion 2026-12-30 ·
NCT07106892 ·
CT.gov ↗ What to watch
HLX43 Phase 2 Cervical Cancer, Ovarian Cancer Est. primary completion 2026-12-31 ·
NCT06769152 ·
CT.gov ↗ What to watch
2027 (6) May 2027 (1) HLX43 + Serplulimab Phase 2 Breast Cancer (Triple Negative Breast Cancer (TNBC)) Est. primary completion 2027-05-15 ·
NCT07487519 ·
CT.gov ↗ What to watch
June 2027 (1) HLX43 + Serplulimab Phase 2 Non Small Cell Lung Cancer, Small Cell Lung Cancer Est. primary completion 2027-06-18 ·
NCT07253142 ·
CT.gov ↗ What to watch
July 2027 (2) HLX15 Phase 3 Newly Diagnosed Multiple Myeloma Est. primary completion 2027-07 ·
NCT06895512 ·
CT.gov ↗ What to watch
August 2027 (1) HLX43 Phase 2 Gastric or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-08-30 ·
NCT07115485 ·
CT.gov ↗ What to watch
December 2027 (1) 2028 (2) February 2028 (1) HLX43 Phase 2 Pancreatic Ductal Adenocarcinoma (PDAC) Est. primary completion 2028-02-21 ·
NCT07301229 ·
CT.gov ↗ What to watch
April 2028 (1) HLX43 Phase 2 Non Small Cell Lung Cancer Est. primary completion 2028-04-20 ·
NCT06907615 ·
CT.gov ↗ What to watch
2030 (1) January 2030 (1) Pimurutamab + HLX43 Phase 2/3 Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Est. primary completion 2030-01-15 ·
NCT07459751 ·
CT.gov ↗ What to watch
2031 (1) See the full readout calendar ↗
Regulatory and conference events (4) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
16 June 2026 Topline result HLX04-O International Phase 3 of HLX04-O vs ranibizumab (NCT04740671) met its primary endpoint February 2026 Filing accepted FHND9041 NMPA accepted the FHND9041 NDA for first-line EGFR 19del NSCLC 13 August 2025 Filing accepted HLX04-O NMPA CDE accepts the NDA for HLX04-O (ophthalmic bevacizumab) in wet AMD CN, NMPA · Shanghai Henlius Biotech ·
Source ↗ 2 April 2025 Topline result HLX04-O China Phase 3 of HLX04-O vs ranibizumab (NCT05003245) met its primary endpoint Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $928M $347M — — report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $797M $256M — — report ↗
Latest financial report · 2025-FY
For FY2025, Henlius reported revenue of $928.13M, up 16.5% YoY, and R&D spend of $346.92M, up 35.4% YoY. Cash and equivalents were not disclosed. In RMB terms, the company recorded net profit of RMB 0.8270B and pre-R&D profit of RMB 2.3425B, up 26.2% YoY, marking its third consecutive year of profitability.
The company targets more than 20 product approvals globally, including more than 15 in the U.S. and Europe. Key pipeline developments include serplulimab’s approvals in Europe and emerging markets, a planned U.S. BLA submission for first-line ES-SCLC in 2026, ongoing phase 3 work for HLX22, early proof-of-concept for HLX43, and ex-China approvals and launches for HLX14. Henlius also reported 27 IND approvals, 28 new marketing approvals across more than 60 countries, and new partnerships with Abbott, Eisai, Lotus, Dr. Reddy’s, and Sandoz.